Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
P38 Inhibitor · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | PLACEBO_COMPARATOR | - |
| P38 Inhibitor (4) 150mg | EXPERIMENTAL | - |
| P38 Inhibitor (4) 25mg | EXPERIMENTAL | - |
| P38 Inhibitor (4) 300mg | EXPERIMENTAL | - |
| P38 Inhibitor (4) 50mg | EXPERIMENTAL | - |
| P38 Inhibitor (4) 75mg | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| P38 Inhibitor (4) | DRUG | 50mg po qd |
| Placebo | DRUG | po qd |
| P38 Inhibitor (4) 150mg | DRUG | 150mg po qd |
| P38 Inhibitor (4) 25mg | DRUG | 25mg po bid |
| P38 Inhibitor (4) 300mg | DRUG | 300mg po qd |
| P38 Inhibitor (4) 50mg | DRUG | 50mg po qd |
| P38 Inhibitor (4) 75mg | DRUG | 75mg po bid |
Inclusion Criteria: * adult patients \>18 years of age, with active RA; * receiving treatment for RA on an outpatient basis; * females of child-bearing potential, or nonsterilized males with partners of child-bearing potential, must use reliable contraception during, and for 4 weeks after, the stud...
Top 20 of 28 competitors
P38 Inhibitor is an investigational small molecule being studied for the treatment of rheumatoid arthritis. It is in Phase 2 clinical development and has been evaluated in patients with active rheumatoid arthritis, both as a monotherapy and in combination with stable methotrexate therapy.
P38 Inhibitor is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with rheumatoid arthritis.
P38 Inhibitor is in Phase 2 clinical development for rheumatoid arthritis. Two Phase 2 trials have been completed, with a total of 578 patients enrolled. The drug is not approved and remains investigational.
P38 Inhibitor has been studied in two completed Phase 2 trials: NCT00303563, a monotherapy study in 204 patients with active rheumatoid arthritis, and NCT00316771, a study in 374 patients on stable methotrexate therapy. Both trials were randomized, double-blind, and placebo-controlled.
Yes, P38 Inhibitor is a small molecule therapeutic being developed for rheumatoid arthritis. It is administered in clinical trials to adult patients aged 18 years and older, with both trials enrolling male and female participants.